MaxQ Medical Secures $31.5 Million to Advance Prostate Imaging Tech

The financing round was led by Atlantic Blue Ventures, S3 Ventures, and Olympus Innovation Ventures, with continued support from Hillside Capital. CEO Amir Tehrani noted that the platform is engineered to balance the durability of traditional resective surgeries with the reduced side-effect profile of current minimally invasive solutions. By integrating imaging and tissue-selective therapy into a single procedure, the system seeks to preserve the urethra while minimizing risks like bleeding and sexual dysfunction.

Technological roots for the company trace back to Stanford University research on semiconductor ultrasound, specifically the work of Professor Pierre Khuri-Yakub, inventor of the Capacitive Micromachined Ultrasonic Transducer. As the first spinout from Orchard Ultrasound Innovation, MaxQ is currently focused on clinical evaluations for benign prostate hyperplasia. Long-term objectives include expanding the technology into focal therapy for cancer and broader diagnostic capabilities, such as tumor mapping and biopsy. While the system is currently investigational and not yet commercially available, the investment signals confidence from major industry players in the potential for ultrasound-driven advancements in urological care.